CombiGene AB (publ) publishes prospectus in connection with the rights issue
The Board of Directors in Combigene AB (“Combigene” or the “Company”), reg. no. 556403-3818, resolved on 18 February 2020 on a new issue of units of not more than MSEK 32.5 with pre-emption rights for the Company’s shareholders (the “Rights Issue”). The Rights Issue includes free warrants (the “Warrants”) of series TO3 and TO4. Subscription and guarantee commitments amounting to MSEK 26, equal to 80 percent of the Rights Issue, have been obtained from external guarantors and the Company’s Board of Directors. With regard to the Rights Issue, the Company publishes a prospectus that has been approved today by the Swedish Financial Supervisory Authority.
– The record date for the Rights Issue was18 March 2020.
– The subscription period in the Rights Issue runs between 20 March 2020 until and including 3 April 2020.
– Trading in unit rights will take place between 20 March 2020 until and including 1 April 2020.
– Subscription for shares by use of Warrants of series TO3 takes place between 17 August 2020 until and including 31 August 2020.
– Subscription for shares by use of Warrants of series TO4 takes place between 16 November 2020 until and including 30 November 2020.
For full information regarding the terms of the Rights Issue, please see the prospectus. For full information regarding the terms of the Warrants of series TO3 and TO3, please see the full terms for the Warrants. The prospectus and the full terms of the Warrants are available on CombiGene’s website: https://combigene.com/foretradesemission-2020/ (Only in swedish) A subscription form will be available on the same website as from the start of the subscription period. All mentioned documents are in Swedish only.
This press release may not be announced, published or distributed, in whole or in part, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa or any other jurisdiction where such is subject to legal restrictions or would require an additional prospectus, registration or any other action to be taken in addition to the requirements under Swedish law. The information in this press release may not be forwarded or reproduced in such a manner that would contravene such restrictions or would require such additional prospectuses, other offer documentation, registrations or other actions. Failure to comply with this instruction may result in a violation of applicable securities legislation. No subscription rights, paid subscribed shares or new shares have been or will be registered under the Securities Act, or with any other securities regulatory authority of any state or other jurisdiction of the United States and no subscription rights, paid subscribed shares or new shares may be offered, sold, resold, transferred, delivered or distributed, directly or indirectly, into or within the United States or on the account of such persons other than pursuant to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act, and in compliance with any applicable securities laws of any state or jurisdiction of the United States.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.